paramount importance of angiotensin receptor neprilysin inhibitor in heart failure management
نویسندگان
چکیده
no abstract#####
منابع مشابه
Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure.
IMPORTANCE Angiotensin receptor neprilysin inhibition (ARNI) therapy provided incremental survival benefit to patients with heart failure and reduced ejection fraction (HFrEF) in clinical trials. To date, estimation of the potential benefits that could be gained from optimal implementation of ARNI therapy at the population level have not been quantified. OBJECTIVE To quantify the projected ga...
متن کاملThe path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
The PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial demonstrated that a new angiotensin receptor antagonist-neprilysin inhibitor was superior to an angiotensin-converting enzyme inhibitor in reducing mortality in patients with heart failure and reduced ejection fraction. This paper traces the research path that ...
متن کاملLCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
Background Natriuretic peptides have potent natriuretic and vasodilator properties, reduce sympathetic drive, inhibit aldosterone secretion and have antiproliferative and antihypertrophic properties [1]. Increasing the concentration of natriuretic peptides through neprilysin (NEP) inhibition thus represents a therapeutic approach with the potential to confer cardiac, vascular and renal protecti...
متن کاملAngiotensin-neprilysin inhibition versus enalapril in heart failure.
BACKGROUND We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either ...
متن کاملORAL PRESENTATION Open Access LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
Background Natriuretic peptides have potent natriuretic and vasodilator properties, reduce sympathetic drive, inhibit aldosterone secretion and have antiproliferative and antihypertrophic properties [1]. Increasing the concentration of natriuretic peptides through neprilysin (NEP) inhibition thus represents a therapeutic approach with the potential to confer cardiac, vascular and renal protecti...
متن کاملAngiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
Heart failure remains a major concern across the globe as life expectancies and delivery of health care continue to improve. There has been a dearth of new developments in heart failure therapies in the last decade until last year, with the release of the results from the PARADIGM-HF Trial heralding the arrival of a promising new class of drug, ie, the angiotensin receptor-neprilysin inhibitor....
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
acta medica iranicaجلد ۵۴، شماره ۱۲، صفحات ۸۲۳-۸۲۴
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023